← Back to Search

Insulin

Insulin (Novolin-R) for Frontotemporal Dementia

Phase 2
Waitlist Available
Led By Michael H Rosenbloom, MD
Research Sponsored by HealthPartners Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study intranasal insulin in patients with Frontotemporal dementia, in order to evaluate the feasibility of the EXAMINER cognitive battery, the ability to recruit subjects, and the safety of intranasal regular insulin administered 20 IU twice per day.

Eligible Conditions
  • Frontotemporal Dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility Measured by EXAMINER Battery
Feasibility Measured by Recruitment
Safety Measured by Total Serious Adverse Events (SAEs) and Adverse Events (AEs)
Secondary outcome measures
Feasibility Measured by Completion of Study
Feasibility Measured by Screen Fails
Safety Measured by Unique Subjects With Serious Adverse Events (SAEs) and Adverse Events (AEs)
Other outcome measures
Pre to Post Appetite Changes by the Appetite and Eating Habit Questionnaire (APEHQ) - Appetite Subscore
Pre to Post Appetite Changes by the Appetite and Eating Habit Questionnaire (APEHQ) - Eating Habits Subscore
Pre to Post Appetite Changes by the Appetite and Eating Habit Questionnaire (APEHQ) - Food Preference Subscore
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Insulin (Novolin-R)Experimental Treatment1 Intervention
Regular insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril) BID

Find a Location

Who is running the clinical trial?

HealthPartners InstituteLead Sponsor
186 Previous Clinical Trials
3,661,438 Total Patients Enrolled
2 Trials studying Frontotemporal Dementia
2,553 Patients Enrolled for Frontotemporal Dementia
Michael H Rosenbloom, MDPrincipal InvestigatorHealthPartners Neurology
8 Previous Clinical Trials
228 Total Patients Enrolled
1 Trials studying Frontotemporal Dementia
3 Patients Enrolled for Frontotemporal Dementia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Intranasal Insulin in Frontotemporal Dementia (FTD)
2019. "Intranasal Insulin in Frontotemporal Dementia (FTD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04115384.
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top